Karuna Therapeutics Inc
Change company Symbol lookup
Select an option...
KRTX Karuna Therapeutics Inc
NVAX Novavax Inc
EBIX Ebix Inc
FCRD First Eagle Alternative Capital BDC Inc
RWAY Runway Growth Finance Corp
LITB LightInTheBox Holding Co Ltd
UEC Uranium Energy Corp
NEE Nextera Energy Inc
MANT ManTech International Corp
AMPE Ampio Pharmaceuticals Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is developing a pipeline of therapeutic programs to address symptoms associated with schizophrenia and psychosis associated with Alzheimer’s disease (AD), as well as various forms of pain. KarXT is a combination of xanomeline and trospium. KarXT combines xanomeline, a muscarinic agonist, with trospium, a muscarinic antagonist, to stimulate muscarinic receptors in the CNS. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms.

Closing Price
$124.47
Day's Change
2.26 (1.85%)
Bid
--
Ask
--
B/A Size
--
Day's High
125.16
Day's Low
119.44
Volume
(Light)
Volume:
134,216

10-day average volume:
192,715
134,216

Company Profile

Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is developing a pipeline of therapeutic programs to address symptoms associated with schizophrenia and psychosis associated with Alzheimer’s disease (AD), as well as various forms of pain. KarXT is a combination of xanomeline and trospium. KarXT combines xanomeline, a muscarinic agonist, with trospium, a muscarinic antagonist, to stimulate muscarinic receptors in the CNS. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
7.11x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

December 2021
Current Month
1.2M
Previous Month
1.3M
Percent of Float
4.31%
Days to Cover
6.5374 Days

Share Information

KRTX is in a share class of common stock
Float
27.5M
Shares Outstanding
29.6M
Institutions Holding Shares
226
95.83%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Steven M. PaulDir.
  • Troy A. IgnelziCFO
  • Andrew Craig MillerCOO
  • Stephen K. BrannanOther
  • Charmaine LykinsOther

Address

Insider Trading

During the most recent quarter, 2K shares were bought, and 96K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.